Atopic Dermatitis

The AJMC® Atopic Dermatitis compendium is a comprehensive resource for clinical news and expert insights for the chronic skin condition that typically develops in early childhood.

Latest News

Atopic Dermatitis Itch. | Image Credit: Pormezz - stock.adobe.com .jpeg
Top Risk Factors for Anxiety, Depression Identified in Atopic Dermatitis

July 1st 2025

This new study identifies key contributors to mental health decline in individuals with atopic dermatitis, highlighting the need for integrated care.

Air pollution and atopic dermatitis | Image Credit: Maggie Shaw-sora.chatgpt.com
Air Pollution Linked to Worse Atopic Dermatitis

June 27th 2025

Atopic dermatitis diagnosis | Image Credit: MP Studio-stock.adobe.com
Dupilumab for Atopic Dermatitis May Increase Psoriasis Risk

June 18th 2025

Pediatric atopic dermatitis | Image Credit: Maggie L. Shaw/sora.chatgpt.com
Pediatric Atopic Dermatitis Linked to Allergy Development

June 13th 2025

Atopic Dermatitis Image Credit: wladimir1804-stock.adobe.com
Oral Ivarmacitinib Shows Promise in Atopic Dermatitis

June 6th 2025

Topical Therapies for the Treatment of Atopic Dermatitis: Balancing Safety, Efficacy, and Access

Develop a deeper understanding of the atopic dermatitis (AD) patient journey, explore topical therapies and treatment sequencing advancements, and gain insight regarding the payer’s perspective on AD therapies.

Atopic Dermatitis Payer Perspectives

More News

itch.
September 14th 2022

Ruxolitinib Cream Linked With Rapid Reduction of Itch in Atopic Dermatitis

Matthew Gavidia
Significantly more patients given ruxolitinib cream vs vehicle demonstrated rapid improvements in itch that were sustained over time.
Jason Ezra Hawkes, MD.
September 10th 2022

Dr Jason Ezra Hawkes on Diagnostic Challenges, Strategies in Atopic Dermatitis

Matthew Gavidia
Jason Ezra Hawkes, MD, MS, FAAD, board-certified dermatologist and associate professor of dermatology at the University of California Davis in Sacramento, spoke on diagnostic challenges for atopic dermatitis and tips for clinicians in screening for the condition.
Adult holding child hand.
September 7th 2022

Early-Onset AD May Affect Cognitive Functioning in Children

Matthew Gavidia
Pediatric patients who developed atopic dermatitis (AD) before 2 years of age had an increased risk of neurodevelopmental dysfunction, including gross and fine motor skills, at 6 years old.
Atopic dermatitis.
August 30th 2022

AD Diagnosis, JAK Inhibitor Use Not Shown to Increase Risk of Venous Thromboembolism

Matthew Gavidia
Patients with atopic dermatitis (AD) were not found to be at greater risk of venous thromboembolism, regardless of Janus kinase inhibitor use, according to this new meta-analysis.
Jason Ezra Hawkes.
August 26th 2022

Dr Jason Ezra Hawkes Discusses How AD Immunology Informs Screening Practices

Matthew Gavidia
Jason Ezra Hawkes, MD, MS, FAAD, board-certified dermatologist and associate professor of dermatology at the University of California Davis in Sacramento, explained the utility of type 2 inflammation pathways and the microbiome in understanding the immune dysregulation associated with atopic dermatitis (AD).
Food.
August 23rd 2022

Benefits of Dietary Elimination May Not Outweigh Risks in Atopic Dermatitis

Matthew Gavidia
Findings of a meta-analysis show that use of dietary elimination had a minimal effect on the severity of atopic dermatitis and may increase the risk of developing immunoglobulin E–mediated food allergy.
biologic.
August 18th 2022

Drug Survival of Dupilumab Affected by Immunosuppressive Therapy, Older Age in AD

Matthew Gavidia
Investigator Global Assessment score of very severe atopic dermatitis (AD) was associated with dupilumab discontinuation due to adverse effects, although generally adequate 1-, 2-, and 3-year drug survival rates were also observed.
Depression.
August 10th 2022

Race, Insurance Type Among Predictors of Depressive Symptoms in Atopic Dermatitis

Matthew Gavidia
Most patients with atopic dermatitis had flunctuating levels of depressive symptoms, with having public or no insurance, more severe itch, and skin pain cited as additional predictors of adverse mental health outcomes.
patient and physician.
August 8th 2022

Investigating Patient Preferences for Atopic Dermatitis Treatment

Matthew Gavidia
European adult patients with atopic dermatitis most valued therapies that had rapid onset, oral administration, and were able to be paused—even at the expense of reduced efficacy.
Exploring Clinical, Diagnostic Features of Photoaggravated Atopic Dermatitis
August 2nd 2022

Exploring Clinical, Diagnostic Features of Photoaggravated Atopic Dermatitis

Matthew Gavidia
Substantially impaired quality of life was shown in patients with photoaggravated atopic dermatitis, with phototesting cited as an effective diagnostic approach in promoting personalized care.
Atopic dermatitis.
July 29th 2022

Overuse of Systemic Corticosteroids, Substantial Cost Burden for AD Seen in Germany

Matthew Gavidia
Systemic corticosteroids were more commonly prescribed vs other systemic drug options in Germany for patients with atopic dermatitis (AD) despite their unfavorable risk-benefit profile, with a substantial economic burden cited among these populations.
Elaine Siegfried, MD.
July 23rd 2022

Dr Elaine Siegfried Discusses Step Edits, Barriers to AD Treatment

Matthew Gavidia
Elaine Siegfried, MD, professor of pediatrics and dermatology, Saint Louis University Health Sciences Center, speaks on step edits and other barriers limiting access to biologic, topical, and other medications for the treatment of atopic dermatitis (AD).
Child patient.
July 20th 2022

Examining the Impact of Atopic Dermatitis Severity on Families of Pediatric Patients

Matthew Gavidia
Increased atopic dermatitis severity in pediatric patients was associated with a greater physical, emotional, social, and economic impact on families.
skin pain/itch.
July 11th 2022

Itch and Skin Pain in Patients With AD Linked With Significant QOL Burden

Matthew Gavidia
The significant quality of life burden associated with symptoms of itching and/or skin pain in patients with atopic dermatitis (AD) may warrant alternate approaches to address unmet needs.
patient speaking with doctor
July 6th 2022

Disease Severity, Time Managing Symptoms Contribute to High Disease Burden for Patients With AD

Lindsey Mulrooney
A majority of patients with moderate or severe atopic dermatitis (AD) reported moderate-to-high negative impacts on quality of life.
Elaine Siegfried, MD.
July 2nd 2022

Dr Elaine Siegfried on Preventive Strategies to Reduce Comorbidity Risk in Atopic Dermatitis

Matthew Gavidia
Elaine Siegfried, MD, professor of pediatrics and dermatology, Saint Louis University Health Sciences Center, addresses the comorbidity profile associated with atopic dermatitis and the utility of disease-modifying drugs to reduce risk of comorbid conditions.
group of diverse teenagers
June 30th 2022

Dupilumab Effective for Pediatric, Adolescent Patients With AD Regardless of Age, Sex, Race

Lindsey Mulrooney
Patients from this diverse cohort experienced improvements in atopic dermatitis (AD) clinical scores after a year or more of treatment with dupilumab.
Robert Sidbury.
June 25th 2022

Dr Robert Sidbury on Promoting Therapeutic Adherence in Pediatric Atopic Dermatitis

Matthew Gavidia
Robert Sidbury, MD, MPH, Chief, Division of Dermatology, Seattle Children's Hospital, speaks on strategies that clinicians can employ to promote adherence of topical and oral medications in pediatric patients with atopic dermatitis.
child with a mask.
June 24th 2022

Study Finds Environmental, Lifestyle Risk Factors of Atopic Dermatitis in Preschool Children

Matthew Gavidia
Several environmental and lifestyle factors were associated with significant risk of atopic dermatitis development in preschool children of Shenzhen, China, including the presence of mold in the child’s room, living in a villa/townhouse, and using composite wood floors.
Elaine Siegfried, MD.
June 16th 2022

Dr Elaine Siegfried Addresses Patient-Centered Therapeutic Management for Atopic Dermatitis

Matthew Gavidia
Elaine Siegfried, MD, professor of pediatrics and dermatology, Saint Louis University Health Sciences Center, discusses therapeutic management considerations for dermatologists in consulting with diverse patients with atopic dermatitis.
FDA Widens Use of Dupilumab to Children With AD as Young as 6 Months
June 9th 2022

FDA Widens Use of Dupilumab to Children With AD as Young as 6 Months

AJMC Staff
The FDA this week expanded the use of dupilumab for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis (AD) whose disease is not controlled with topical prescription therapies or when those treatments can't be used.
Patient and physician.
June 8th 2022

Dupilumab Efficacy in Asthma, AD, EoE, and CRSwNP Not Affected By Eosinophil Count

Matthew Gavidia
Dupilumab-induced increases in mean eosinophil counts were shown to wane over time in patients with asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and atopic dermatitis (AD), with incidence of eosinophilia not shown to reduce efficacy of the biologic.
puzzled brain.
June 7th 2022

Risk of Dementia Elevated in Patients With Atopic Dermatitis

Matthew Gavidia
A study of UK electronic health record data indicated patients with atopic dermatitis (AD) showed an increased risk of dementia compared with the general population.
Robert Sidbury, MD, MPH.
June 3rd 2022

Dr Robert Sidbury Reviews Novel Topical, Systemic Therapies for Pediatric Atopic Dermatitis

Matthew Gavidia
Robert Sidbury, MD, MPH, chief, Division of Dermatology, Seattle Children's Hospital, provides an overview of recent approvals and indications under consideration for the treatment of pediatric atopic dermatitis.
Food.
May 31st 2022

Food Sensitization in Early-Onset AD Linked With Later Allergic Respiratory Diseases

Matthew Gavidia
Pediatric patients with early-onset atopic dermatitis (AD) who reported incidence of food sensitization were associated with later allergic respiratory diseases, in which persistence of AD was linked with multiple food allergies.
doctor inspecting skin.
May 26th 2022

Greater Atopic Dermatitis Severity May Increase Risk of Certain Cancers

Matthew Gavidia
Pediatric and adult patients reporting more severe disease courses of atopic dermatitis had a greater risk of select cancers, particularly lymphoma.
Elaine Siegfried, MD
May 19th 2022

Dr Elaine Siegfried Discusses Skin Color, Socioeconomic Implications of Atopic Dermatitis Management

Matthew Gavidia
Elaine Siegfried, MD, professor of pediatrics and dermatology, Saint Louis University Health Sciences Center, explains the impact of socioeconomic status on the management of atopic dermatitis in the clinical setting.
Atopic dermatitis.
May 17th 2022

Dupilumab Clinically Effective Long Term for Moderate to Severe Pediatric Atopic Dermatitis

Matthew Gavidia
Findings of the 52-week phase 3 LIBERTY AD PED-OLE trial showed dupilumab to have an adequate safety profile and incremental clinical benefit with continued use among pediatric patients with moderate to severe atopic dermatitis.
Robert Sidbury, MD, MPH.
May 13th 2022

Dr Robert Sidbury Discusses Strategies to Promote Earlier Uptake of Novel Atopic Dermatitis Therapies

Matthew Gavidia
Robert Sidbury, MD, MPH, chief, division of dermatology, Seattle Children's Hospital, discussed the emergence of effective therapies for the management of atopic dermatitis and how dermatologists and other providers involved in patient care can better promote earlier use of these treatments.
Stethoscope next to a teddy bear and blocks.
May 10th 2022

Study Shows Caregivers Prefer Dermatology Specialists Over PCPs for Pediatric Atopic Dermatitis

Matthew Gavidia
Dermatology specialists were cited by diverse caregivers of children with atopic dermatitis (AD) to provide enhanced care delivery and improved AD disease control compared with primary care providers.
<12345678>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo